Trial Profile
Study to evaluate the association between Cerebrospinal fluid (CSF) phosphorylated-tau (P-tau) and total-tau (T-tau) with the novel tau imaging agent [18F]MK6240 in patients with Dementias and healthy Controls
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2018
Price :
$35
*
At a glance
- Drugs Florquinitau F18 (Primary)
- Indications Alzheimer's disease; Dementia; Mild cognitive impairment
- Focus Diagnostic use
- 03 Oct 2018 New trial record